Danielle Golovin

Florida

I love science, art, education, animals, board games, cooking and volleyball. Central Michigan (B.S.) and Vanderbilt University (Ph.D.) alum.

Featured in: Favicon

biocentury.com Favicon

zephyrnet.com

Articles

Beech: Treating pregnancy complications without affecting the fetus

2 days ago | biocentury.com | Danielle Golovin

ARTICLE | Emerging Company ProfileSwitzerland-based newco has new grant from Gates Foundation to advance a preeclampsia treatment that doesn’t cross the placenta By Danielle Golovin, Senior Biopharma AnalystFor decades, drug development for pregnancy complications has been paralyzed by fear of harming the fetus — leaving physicians with few safe options to treat even life-threatening maternal conditions.
Science Spotlight: Targets to enhance CAR-NK cell therapies

4 days ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes Recode’s multi-organ targeted LNPs and tau-vulnerable neurons in Alzheimer’s By Danielle Golovin, Senior Biopharma AnalystTwo recent papers describe intracellular checkpoints that limit NK cell antitumor activity, suggesting targets to enhance the efficacy of CAR-NK cell therapies.
Fibromyalgia drug nearing approval after a 16-year lull

4 days ago | biocentury.com | Danielle Golovin

ARTICLE | Product DevelopmentAs Tonix awaits FDA decision, Axsome receives refuse-to-file letter By Danielle Golovin, Senior Biopharma AnalystAfter 16 years without a new approval, fibromyalgia patients may be on the cusp of getting a therapy that improves pain, sleep and fatigue — the triad of symptoms that define the chronic condition.
Can U.S. science funding cuts spark collaboration? A Perspective

2 weeks ago | biocentury.com | Danielle Golovin

ARTICLE | Editor's CommentaryThe proposed NIH cuts are forcing tough conversations—but they could also accelerate smarter, more collaborative approaches to translational science By Danielle Golovin, Senior Biopharma AnalystThe U.S. government’s proposed science funding cuts have left many academics and biotech start-ups reeling as they face an uncertain future with few clear ways to stay afloat.
Science Spotlight: Brain endothelial cell AAVs, prenatal ASO for SMA

3 weeks ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes published innovations with links to newcos By Danielle Golovin, Senior Biopharma AnalystA team from University of California Irvine developed adeno-associated viral (AAV) vectors targeting brain endothelial cells, which could become vectors for delivering transgenes to treat neurological diseases involving the blood-brain barrier.
Glycoera using megaround for precision approach to immunology

3 weeks ago | biocentury.com | Danielle Golovin

ARTICLE | FinanceWith new $130M series B, the company is using an extracellular protein degrader to improve speed and depth of IgG4 removal By Danielle Golovin, Senior Biopharma AnalystWith an approach to depleting autoantibodies that’s designed to be more precise than current treatments, Glycoera has drawn a $130 million series B round to take its extracellular protein degrader program into the clinic.
Decoding the molecular roots of pregnancy complications: Literature Dive

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBlueprints for biomarker discovery and precision medicine in maternal-fetal health By Danielle Golovin, Senior Biopharma Analyst Half a dozen recent publications offer molecular resources for understanding the biology of pregnancy, identifying biomarkers and guiding development of targeted therapies and preventive strategies for pregnancy-related conditions.
Paving the way to more effective fertility treatments: Literature Dive

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationMulti-omic insights point to improved embryo selection and IVF outcomes By Danielle Golovin, Senior Biopharma AnalystScientists are laying the groundwork for more precise, personalized fertility diagnostics and treatments by mapping the molecular landscape of early human reproduction, from embryo development to endometrial receptivity.
Science Spotlight: Novartis’ inhibitor for NRAS-mutant cancers

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes degraders for cancer and an inhibitor for Alzheimer’s By Danielle Golovin, Senior Biopharma Analyst A Novartis AG (SIX:NOVN; NYSE:NVS) research team identified a druggable component of the mutant NRAS complex and discovered small molecules that disrupt the interaction. The findings add to the toolbox for drugging activating mutations in RAS family members beyond KRAS.
Expressionedits: Multifold improvement in protein production

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Emerging Company Profile University of Cambridge spinout enhances gene expression by adding in multiple short non-coding regions By Danielle Golovin, Senior Biopharma AnalystMethods to drive up protein expression could support translational research, solve manufacturing bottlenecks for protein therapeutics, and improve gene therapy efficiency to allow for lower doses and improved safety.